Method of the Year 2019: Single cell multi-omics

Single cell multi-Omics selected as Method of the Year skylarvision from Pixabay

Single cell multi-Omics selected as Method of the Year 2019 by Nature Methods

Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology

06 January 2020 - Nature Methods announced that single cell multimodal omics was selected as Method of the Year 2019. It specially recognizes the recent advance in single cell analysis technology, where multiple types of measurement can simultaneous be made on single cells in the same experiment.

Single cell analysis is a powerful tool that profiles each individual cells in depth. It promises to transform scientific research and medical treatment. Cancer, for example, often starts with subtle changes in one or a small group of cells. Even within the same patient, different tumour cells may show different characteristics and therefore different drug responses. Single cell analysis allows scientist and clinicians to look into this heterogeneity and develop targeted therapy.

Now, by combining different readouts, such as RNA and protein expression, single cell analysis can provide greater value than the sum of the parts. The Nature Method article also pointed out that development and adoption of single cell multi-omics will generate rich datasets, which will require more sophisticated data analysis tools to fully decipher the information.

This is not the first time that single cell analysis is featured by top scientific journals. In 2013, Single cell DNA and RNA sequencing was selected as the Method of the Year by Nature Methods, where the research community started to widely adopt single cell sequencing techniques in order to gain deeper insight into the heterogeneity of biology.

In 2018, development cell by cell using single cell RNA sequencing was selected as the Breakthrough of the Year 2018 by Science Magazine. Single cell RNAseq enables scientists to track individual cells in development and disease, and to understand their interaction.

Read the original article at

Contact us

For media queries, please contact:

Dr Andreas Schmidt

About Proteona

Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.